Qiu Guanglin, Li Xuqi, Wei Chao, Che Xiangming, He Shicai, Lu Jing, Wang Shufeng, Pang Ke, Fan Lin
Department of General Surgery, The First Affiliated Hospital Medical College of Xi'an Jiaotong University, Xi'an 710061, China.
Xi'an Health School, Xi'an 710054, China.
Dis Markers. 2016;2016:6869415. doi: 10.1155/2016/6869415. Epub 2016 Dec 14.
. Sirtuin 1 (SIRT1) can induce autophagy through deacetylation of Beclin-1 and other autophagy mediators. However, the relationship between SIRT1 and autophagy in GC has not been defined. Therefore, the aim of this study was to confirm the prognostic value of SIRT1 and Beclin-1 and their relationship in GC patients. . Transmission electron microscopy (TEM) was performed to examine the autophagy in GC patients. Immunohistochemistry was used to examine the expression of SIRT1, Beclin-1 in GC, and adjacent nonneoplastic mucosa. . In 7 out of 8 GC patients' samples examined by TEM, more autophagic vesicles were observed in GC tissues compared to adjacent nonneoplastic mucosa tissue. A positive correlation between SIRT1 and Beclin-1 expression was observed. Furthermore, Beclin-1 or SIRT1 expression alone or their combined expression were significantly correlated with advanced clinicopathological parameters. High Beclin-1 and SIRT1 expression alone and their combined high expression predicted shorter overall survival and relapse-free survival. Both high Beclin-1 and SIRT1 expressions were independent prognostic factors for poor survival of GC. . Based on our results we can conclude that SIRT1 and Beclin-1 expression alone or in combination can be used as prognostic indicator and may represent new therapeutic targets in GC.
沉默调节蛋白1(SIRT1)可通过使Beclin-1和其他自噬调节因子去乙酰化来诱导自噬。然而,SIRT1与胃癌中自噬的关系尚未明确。因此,本研究的目的是证实SIRT1和Beclin-1在胃癌患者中的预后价值及其相互关系。通过透射电子显微镜(TEM)检测胃癌患者的自噬情况。采用免疫组织化学法检测SIRT1、Beclin-1在胃癌组织及癌旁非肿瘤黏膜中的表达。在8例接受TEM检查的胃癌患者样本中,有7例显示,与癌旁非肿瘤黏膜组织相比,胃癌组织中观察到更多自噬泡。观察到SIRT1与Beclin-1表达呈正相关。此外,单独的Beclin-1或SIRT1表达或二者联合表达均与晚期临床病理参数显著相关。单独的高Beclin-1和SIRT1表达及其联合高表达预示着总生存期和无复发生存期较短。高Beclin-1和SIRT1表达均是胃癌患者不良生存的独立预后因素。基于我们的研究结果,我们可以得出结论:单独或联合的SIRT1和Beclin-1表达可作为预后指标,可能代表胃癌新的治疗靶点。